Updates are available Correction dated 2024-09-25
Click to view Correction: https://doi.org/10.1038/s44318-024-00247-6
-
Authors
Kar, Pulak
Chatrin, Chatrin
Đukić, Nina https://orcid.org/0009-0004-6120-6421
Suyari, Osamu https://orcid.org/0009-0008-3258-8722
Schuller, Marion
Zhu, Kang https://orcid.org/0000-0003-2623-3331
Prokhorova, Evgeniia
Bigot, Nicolas https://orcid.org/0000-0002-4247-0217
Baretić, Domagoj
Ahel, Juraj https://orcid.org/0000-0003-0293-1063
Elsborg, Jonas Damgaard https://orcid.org/0000-0002-1506-4280
Nielsen, Michael L
Clausen, Tim
Huet, Sébastien
Niepel, Mario https://orcid.org/0000-0003-1415-6295
Sanyal, Sumana https://orcid.org/0000-0002-6230-5366
Ahel, Dragana
Smith, Rebecca https://orcid.org/0000-0002-1658-5635
Ahel, Ivan https://orcid.org/0000-0002-9446-3756
-
Funding
Funding for this research was provided by:
UKRI | Biotechnology and Biological Sciences Research Council (BB/R007195/1)
UKRI | Biotechnology and Biological Sciences Research Council (BB/W016613/1)
Wellcome Trust (210634)
Wellcome Trust (223107)
Oxford University Challenge Seed Fund (USCF 456)
Edward Penley Abraham Research Fund
Ovarian Cancer Research Alliance (813369)
Agence Nationale de la Recherche (ANR-22-CE12-0039)
Fondation ARC pour la Recherche sur le Cancer (ARCPJA2022060005190)
Ligue Contre le Cancer (CD53)
- License Information
-
More Information
Article History
Received: 7 October 2023
Revised: 1 May 2024
Accepted: 8 May 2024
First Online: 4 June 2024
Change Date: 25 September 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s44318-024-00247-6
Disclosure and competing interests statement
: MN is an employee and shareholder of Ribon Therapeutics. EP is an employee of Vertex Pharmaceuticals and may own stock or stock options in that company. All other authors declare that they have no competing interests.
